HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy

Clinical trial NCT05322720 · UNKNOWN

Trial details

NCT number: NCT05322720
Sponsor: Taizhou EOC Pharma Co., Ltd.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Solid Tumor, Adult

Start date: 2022-04-01
Primary completion: 2023-03-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.